MetLife Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-60,514
| Closed | -$184K | – | 2845 |
|
|
2024
Q4 | $184K | Buy |
60,514
+4,235
| +8% | +$18.4K | ﹤0.01% | 2343 |
|
|
2024
Q3 | $292K | Buy |
56,279
+1,010
| +2% | +$5.02K | ﹤0.01% | 2079 |
|
|
2024
Q2 | $142K | Buy |
55,269
+18,846
| +52% | +$64.4K | ﹤0.01% | 2440 |
|
|
2024
Q1 | $179K | Sell |
36,423
-7,557
| -17% | -$44.7K | ﹤0.01% | 2255 |
|
|
2023
Q4 | $387K | Hold |
43,980
| – | – | ﹤0.01% | 1838 |
|
|
2023
Q3 | $504K | Hold |
43,980
| – | – | ﹤0.01% | 1631 |
|
|
2023
Q2 | $1.11M | Buy |
43,980
+1,653
| +4% | +$51.5K | 0.01% | 1211 |
|
|
2023
Q1 | $1.36M | Hold |
42,327
| – | – | 0.01% | 1070 |
|
|
2022
Q4 | $781K | Buy |
42,327
+3,200
| +8% | +$73.2K | 0.01% | 1353 |
|
|
2022
Q3 | $1.06M | Hold |
39,127
| – | – | 0.01% | 1160 |
|
|
2022
Q2 | $541K | Hold |
39,127
| – | – | ﹤0.01% | 1597 |
|
|
2022
Q1 | $763K | Buy |
39,127
+13,694
| +54% | +$208K | ﹤0.01% | 1501 |
|
|
2021
Q4 | $415K | Hold |
25,433
| – | – | ﹤0.01% | 1605 |
|
|
2021
Q3 | $709K | Hold |
25,433
| – | – | 0.01% | 1322 |
|
|
2021
Q2 | $754K | Hold |
25,433
| – | – | 0.01% | 1335 |
|
|
2021
Q1 | $711K | Hold |
25,433
| – | – | 0.01% | 1320 |
|
|
2020
Q4 | $721K | Hold |
25,433
| – | – | 0.01% | 1283 |
|
|
2020
Q3 | $639K | Hold |
25,433
| – | – | 0.01% | 1242 |
|
|
2020
Q2 | $621K | Buy |
25,433
+4,085
| +19% | +$80.6K | 0.01% | 1259 |
|
|
2020
Q1 | $316K | Hold |
21,348
| – | – | ﹤0.01% | 1456 |
|
|
2019
Q4 | $346K | Hold |
21,348
| – | – | ﹤0.01% | 1654 |
|
|
2019
Q3 | $278K | Hold |
21,348
| – | – | ﹤0.01% | 1752 |
|
|
2019
Q2 | $277K | Buy |
21,348
+5,816
| +37% | +$73.3K | ﹤0.01% | 1840 |
|
|
2019
Q1 | $245K | Hold |
15,532
| – | – | ﹤0.01% | 1867 |
|
|
2018
Q4 | $313K | Hold |
15,532
| – | – | ﹤0.01% | 1652 |
|
|
2018
Q3 | $386K | Hold |
15,532
| – | – | ﹤0.01% | 1700 |
|
|
2018
Q2 | $426K | Buy |
15,532
+4,557
| +42% | +$137K | 0.01% | 1502 |
|
|
2018
Q1 | $338K | Hold |
10,975
| – | – | ﹤0.01% | 1620 |
|
|
2017
Q4 | $392K | Buy |
+10,975
| New | +$315K | ﹤0.01% | 1542 |
|
Other funds holding RVNC
MetLife Investment Management's RVNC Position: Q1 2025 in Review
MetLife Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 60,514 shares — an estimated $184K sold.
MetLife Investment Management first reported a position in RVNC in Q4 2017 and held it in 29 quarters. The position peaked at $1.36M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- MetLife Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- MetLife Investment Management sold 60,514 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $184K.
- MetLife Investment Management first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 29 quarters.
- MetLife Investment Management's Revance Therapeutics, Inc. position peaked at $1.36M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.